DK0852491T3 - Anvendelse af heparinaser til at mindske inflammatoriske responser - Google Patents

Anvendelse af heparinaser til at mindske inflammatoriske responser

Info

Publication number: DK0852491T3
Authority: DK; Denmark
Prior art keywords: heparinase; endothelium; localized; inflammatory responses; heparin
Prior art date: 1995-09-29

Application number

DK96936052T

Other languages

English (en)

Inventor

D Clark Bennett

Elizabeth Cauchon

Dominique Fink

Brigette Grouix

Ariane Hsia

Pamela Danagher

Joseph Zimmerman

Original Assignee

Biomarin Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-09-29

Filing date

1996-09-27

Publication date

2004-12-20

1996-09-27 Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc

2004-12-20 Application granted granted Critical

2004-12-20 Publication of DK0852491T3 publication Critical patent/DK0852491T3/da

Links

108010022901 Heparin Lyase Proteins 0.000 title abstract 8
230000028709 inflammatory response Effects 0.000 title abstract 2
229920002971 Heparan sulfate Polymers 0.000 abstract 4
210000003038 endothelium Anatomy 0.000 abstract 4
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 abstract 2
229960002897 heparin Drugs 0.000 abstract 2
210000000265 leukocyte Anatomy 0.000 abstract 2
102000019034 Chemokines Human genes 0.000 abstract 1
108010012236 Chemokines Proteins 0.000 abstract 1
206010015866 Extravasation Diseases 0.000 abstract 1
206010061218 Inflammation Diseases 0.000 abstract 1
238000009825 accumulation Methods 0.000 abstract 1
210000002469 basement membrane Anatomy 0.000 abstract 1
230000029087 digestion Effects 0.000 abstract 1
210000002889 endothelial cell Anatomy 0.000 abstract 1
230000036251 extravasation Effects 0.000 abstract 1
230000004054 inflammatory process Effects 0.000 abstract 1
108020001756 ligand binding domains Proteins 0.000 abstract 1
238000005096 rolling process Methods 0.000 abstract 1
230000008685 targeting Effects 0.000 abstract 1
210000001519 tissue Anatomy 0.000 abstract 1
230000002792 vascular Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Microbiology (AREA)
Immunology (AREA)
General Engineering & Computer Science (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Enzymes And Modification Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)

DK96936052T 1995-09-29 1996-09-27 Anvendelse af heparinaser til at mindske inflammatoriske responser DK0852491T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US462295P	1995-09-29	1995-09-29
EP96936052A EP0852491B1 (en)	1995-09-29	1996-09-27	Use of heparinases to decrease inflammatory responses
US08/722,659 US20010006635A1 (en)	1995-09-29	1996-09-27	Use of heparinase to decrease inflammatory responses

Publications (1)

Publication Number	Publication Date
DK0852491T3 true DK0852491T3 (da)	2004-12-20

Family

ID=26673252

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK96936052T DK0852491T3 (da)	1995-09-29	1996-09-27	Anvendelse af heparinaser til at mindske inflammatoriske responser

Country Status (11)

Country	Link
US (3)	US20010006635A1 (da)
EP (2)	EP0852491B1 (da)
JP (1)	JP3713276B2 (da)
AT (1)	ATE273020T1 (da)
AU (1)	AU703394B2 (da)
CA (1)	CA2233343A1 (da)
DE (1)	DE69633127T2 (da)
DK (1)	DK0852491T3 (da)
ES (1)	ES2227611T3 (da)
PT (1)	PT852491E (da)
WO (1)	WO1997011684A1 (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6153187A (en) *	1997-09-02	2000-11-28	Insight Strategy & Marketing Ltd.	Use of glycosaminoglycans degrading enzymes for management of airway associated diseases
CA2242693C (en) *	1997-09-04	2002-09-17	Becton, Dickinson And Company	Additive formulation and method of use thereof
WO1999043830A2 (en)	1998-02-24	1999-09-02	Pharmacia & Upjohn Company	Human platelet heparanase polypeptides, polynucleotide molecules that encode them, and methods for the identification of compounds that alter heparanase activity
WO2000012726A2 (en)	1998-08-27	2000-03-09	Massachusetts Institute Of Technology	Rationally designed heparinases derived from heparinase i and ii
US7056504B1 (en)	1998-08-27	2006-06-06	Massachusetts Institute Of Technology	Rationally designed heparinases derived from heparinase I and II
EP1010762A1 (en) *	1998-12-02	2000-06-21	Aventis Behring Gesellschaft mit beschränkter Haftung	DNA constructs of blood clotting factors and P-Selectin
EP1026250A1 (en)	1998-12-02	2000-08-09	Aventis Behring GmbH	DNA-constructs of blood clotting factors and P-selectin
CA2370539C (en)	1999-04-23	2009-01-06	Massachusetts Institute Of Technology	System and method for notating polymers
DK1240313T3 (da)	1999-12-22	2006-11-27	Ucb Sa	Enzymer, som er homologe med heparanase og splejsningsvarianter deraf
WO2001066772A2 (en)	2000-03-08	2001-09-13	Massachusetts Institute Of Technology	Heparinase iii and uses thereof
US7083937B2 (en)	2000-09-12	2006-08-01	Massachusetts Institute Of Technology	Methods and products related to the analysis of polysaccarides
AU2440802A (en)	2000-10-18	2002-04-29	Massachusetts Inst Technology	Methods and products related to pulmonary delivery of polysaccharides
US7629309B2 (en) *	2002-05-29	2009-12-08	Zystor Therapeutics, Inc.	Targeted therapeutic proteins
US7560424B2 (en) *	2001-04-30	2009-07-14	Zystor Therapeutics, Inc.	Targeted therapeutic proteins
ES2300439T3 (es) *	2001-04-30	2008-06-16	Zystor Therapeutics , Inc.	Reconocimiento subcelular de proteinas terapeuticas.
US20040005309A1 (en) *	2002-05-29	2004-01-08	Symbiontics, Inc.	Targeted therapeutic proteins
US20030072761A1 (en) *	2001-10-16	2003-04-17	Lebowitz Jonathan	Methods and compositions for targeting proteins across the blood brain barrier
US7772185B2 (en) *	2004-01-30	2010-08-10	Emory University	Method for promoting axonal outgrowth in damaged nerves
CN1922313B (zh) *	2004-02-10	2011-10-26	生物马林医药公司	酸性α-糖苷酶及其片段
CN1312183C (zh) *	2004-05-19	2007-04-25	清华大学	一种肝素酶i融合蛋白及其编码基因与表达方法
CN100344769C (zh) *	2005-08-04	2007-10-24	清华大学	一种制备低分子量肝素的方法
US7691613B2 (en) *	2006-11-03	2010-04-06	Momenta Pharmaceuticals, Inc.	Glycosaminoglycan lyase IV and uses thereof
US7767420B2 (en)	2005-11-03	2010-08-03	Momenta Pharmaceuticals, Inc.	Heparan sulfate glycosaminoglycan lyase and uses thereof
US7691612B2 (en)	2005-11-03	2010-04-06	Momenta Pharmaceuticals, Inc.	Heparan sulfate glycosaminoglycan lyase and uses thereof
US20090117091A1 (en) *	2006-11-13	2009-05-07	Lebowitz Jonathan	Methods for treating pompe disease
BRPI0912225A2 (pt)	2008-05-07	2018-03-20	Zystor Therapeutics, Inc.	peptídeos de direcionamento lisossomais e usos dos mesmos
EP2475376B1 (en)	2009-06-17	2016-03-30	BioMarin Pharmaceutical Inc.	Formulations for lysosomal enzymes
AU2013380234B2 (en) *	2013-02-28	2018-06-14	Kao Corporation	Composition and process for semi-permanent straightening of hair
EP3579897A4 (en)	2017-03-10	2020-12-30	The University of North Carolina at Chapel Hill	SHORT-ACTING HEPARIN-BASED ANTICOAGULANT COMPOUNDS AND METHODS
WO2019010216A1 (en)	2017-07-03	2019-01-10	The University Of North Carolina At Chapel Hill	ENZYMATIC SYNTHESIS OF HOMOGENEOUS CHONDROITIN SULFATE OLIGOSACCHARIDES
WO2019090203A1 (en)	2017-11-03	2019-05-09	The University Of North Carolina At Chapel Hill	Sulfated oligosaccharides having anti-inflammatory activity
US11633424B2 (en)	2018-06-20	2023-04-25	The University Of North Carolina At Chapel Hill	Cell protective methods and compositions
JP7801217B2 (ja)	2019-11-13	2026-01-16	ザユニバーシティオブノースカロライナアットチャペルヒル	肝虚血再灌流障害におけるヘパラン硫酸（ｈｓ）オリゴ糖の効果

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB941664A (en) *	1959-02-19	1963-11-13	Henry Thompson Stanton Jr	Buccal or sublingual tablet containing carbohydra e enzyme for controlling inflammation
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
IL85145A (en) *	1987-01-23	1994-08-26	Univ Australian	Anti-metastatic pharmacological or veterinary preparations containing modified herpin with reduced anticoagulant activity
US5169772A (en) *	1988-06-06	1992-12-08	Massachusetts Institute Of Technology	Large scale method for purification of high purity heparinase from flavobacterium heparinum
ATE167230T1 (de)	1989-08-23	1998-06-15	Hadassah Med Org	Wundheilmittel enthaltend heparanase
US5099855A (en)	1989-11-09	1992-03-31	State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University	Methods of and apparatus for monitoring respiration and conductive gel used therewith
JPH06500555A (ja) *	1990-08-27	1994-01-20	カイロン　コーポレイション	病気の処置のためのペプチドの薬物
US5270197A (en)	1990-12-20	1993-12-14	The Children's Medical Center Corporation	Cells expressing a substantial number of surface high affinity HBGF receptors but relatively few low affinity HBGF binding sites and system for assaying binding to HBGF receptor
US5714376A (en)	1991-10-23	1998-02-03	Massachusetts Institute Of Technology	Heparinase gene from flavobacterium heparinum
DK75593D0 (da)	1993-06-25	1993-06-25	Novo Nordisk As
CA2176934A1 (en)	1993-11-17	1995-05-26	Ramnath Sasisekharan	Method for inhibiting angiogenesis using heparinase
US5997863A (en) *	1994-07-08	1999-12-07	Ibex Technologies R And D, Inc.	Attenuation of wound healing processes

1996
- 1996-09-27 DE DE69633127T patent/DE69633127T2/de not_active Expired - Fee Related
- 1996-09-27 ES ES96936052T patent/ES2227611T3/es not_active Expired - Lifetime
- 1996-09-27 WO PCT/US1996/015593 patent/WO1997011684A1/en not_active Ceased
- 1996-09-27 EP EP96936052A patent/EP0852491B1/en not_active Expired - Lifetime
- 1996-09-27 PT PT96936052T patent/PT852491E/pt unknown
- 1996-09-27 AU AU73791/96A patent/AU703394B2/en not_active Ceased
- 1996-09-27 JP JP51372397A patent/JP3713276B2/ja not_active Expired - Fee Related
- 1996-09-27 AT AT96936052T patent/ATE273020T1/de not_active IP Right Cessation
- 1996-09-27 CA CA002233343A patent/CA2233343A1/en not_active Abandoned
- 1996-09-27 EP EP04076600A patent/EP1552846A3/en not_active Withdrawn
- 1996-09-27 US US08/722,659 patent/US20010006635A1/en not_active Abandoned
- 1996-09-27 DK DK96936052T patent/DK0852491T3/da active
2005
- 2005-05-02 US US11/118,477 patent/US20050191288A1/en not_active Abandoned
2006
- 2006-02-22 US US11/357,967 patent/US7264799B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US7264799B2 (en)	2007-09-04
DE69633127T2 (de)	2005-08-04
US20010006635A1 (en)	2001-07-05
CA2233343A1 (en)	1997-04-03
JP3713276B2 (ja)	2005-11-09
AU703394B2 (en)	1999-03-25
US20060140928A1 (en)	2006-06-29
DE69633127D1 (de)	2004-09-16
EP1552846A2 (en)	2005-07-13
EP0852491A1 (en)	1998-07-15
WO1997011684A1 (en)	1997-04-03
US20050191288A1 (en)	2005-09-01
EP1552846A3 (en)	2008-05-07
EP0852491A4 (en)	2002-08-07
JPH11512721A (ja)	1999-11-02
ES2227611T3 (es)	2005-04-01
AU7379196A (en)	1997-04-17
ATE273020T1 (de)	2004-08-15
PT852491E (pt)	2004-11-30
EP0852491B1 (en)	2004-08-11

Publication	Publication Date	Title
DK0852491T3 (da)	2004-12-20	Anvendelse af heparinaser til at mindske inflammatoriske responser
EP0701455A4 (en)	1998-01-07	PLASMA-LIKE SOLUTION
US5872109A (en)	1999-02-16	Anti-inflammatory agent
Liangos et al.	2006	Unresolved Issues in Dialysis: Long‐Term Management of the Tunneled Venous Catheter
ES2069287T3 (es)	1995-05-01	Cateter de doble paso precurvado.
ATE310563T1 (de)	2005-12-15	Intravenöse herzleitung mit verstärktem befestigungssegment
WO1992005748A1 (en)	1992-04-16	Soluble hirudin conjugates
Downing et al.	1996	Neutrophils are the initial cell type identified in deep venous thrombosis induced vein wall inflammation
DK0565863T3 (da)	1997-12-15	Semisyntetiske clycosaminoglycaner med heparin- eller heparanstruktur af i 2-stillingen modificeret alfa-L-iduron-2-O-sulfatsyre
ATE82517T1 (de)	1992-12-15	Katheter.
Bino et al.	1982	The kidney is the main site of interferon degradation
ATE421319T1 (de)	2009-02-15	Mit s-nitrosothiol angereicherte erythrocyten und deren verwendung
Cahalon et al.	1997	Heparin disaccharides inhibit tumor necrosis factor-alpha production by macrophages and arrest immune inflammation in rodents.
Shimada et al.	1980	Spontaneous stomach ulcer in genetically mast-cell depleted W/W v mice
PT1058544E (pt)	2005-04-29	Inibicao da actividade do tnf
CA2159485A1 (en)	1994-10-13	Anti-oxydant alkylaryl polyether alcohol polymers
TR200501763T1 (tr)	2009-03-23	T
WO2001019376A3 (en)	2001-12-13	METHOD OF INHIBITING NF-λB WITH HEPARIN, FOR TREATING CARDIOVASCULAR DISEASES AND INFLAMMATIONS
Fukatsu et al.	1999	Concomitant increase in neutrophil adhesion to inflammatory peritoneum and remote organs during peritonitis
EP1164145A3 (en)	2002-01-30	Non-anticoagulant desulfated heparins as medicaments
ITMI931175A0 (it)	1993-06-04	Polisaccaridi ad elevata attivita' antitrombotica e anticoagulante
AU7296600A (en)	2001-03-26	Use of a low molecular weight sulphated polysaccharide to obtain a medicine with antithrombotic activity
ATE81021T1 (de)	1992-10-15	Neutralisierung von heparin.
SE9303787D0 (sv)	1993-11-17	Läkemedel för infusionsbehandling
Stasko et al.	2003	Increased soluble thrombomodulin in hemodialysis patients with long-term erythropoietin treatment: what does it reflect?